Pipeline Pipeline Overview

We leverage our OMEGA platform to advance a robust pipeline of development candidates that target a broad range of diseases.

Target Gene(s)

Indication

Discovery

Preclinical

Phase 1/2

Phase 3

Collaboration

Oncology

MYC
(OTX-2002*)

Hepatocellular carcinoma

Discovery

Preclinical

Phase 1/2

Phase 3

Phase 1/2 MYCHELANGELO™ Study

MYC
(OTX-2101)

Non-small cell lung cancer

Discovery

Preclinical

Phase 1/2

Phase 3

IND-Enabling Studies Ongoing

Undisclosed

Multiple

Discovery

Preclinical

Phase 1/2

Phase 3

Multigenic Diseases

CXCL 1-8

Inflammation / immunology

Discovery

Preclinical

Phase 1/2

Phase 3

Undisclosed

Idiopathic pulmonary fibrosis

Discovery

Preclinical

Phase 1/2

Phase 3

Undisclosed

Obesity

Discovery

Preclinical

Phase 1/2

Phase 3

Regenerative Medicine

HNF4A

Liver regeneration

Discovery

Preclinical

Phase 1/2

Phase 3

Undisclosed

Multiple

Discovery

Preclinical

Phase 1/2

Phase 3

Monogenic Diseases

SFRP1

Alopecia

Discovery

Preclinical

Phase 1/2

Phase 3

Additional gene targets across multiple disease processes screened and characterized; Ready to enter early development.

*In November 2022, OTX-2002 received Orphan Drug Designation from the FDA for the treatment of hepatocellular carcinoma

Learn more about our policy on expanded access to investigational drugs.

Scroll to Top